Guardant Health (NASDAQ:GH) Posts Earnings Results, Beats Expectations By $0.46 EPS

Guardant Health (NASDAQ:GH) released its earnings results on Thursday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.46, FiscalAI reports. The business had revenue of $360.98 million for the quarter, compared to analyst estimates of $350.72 million.

Here are the key takeaways from Guardant Health’s conference call:

• Revenue growth accelerated, and Guardant raised its 2026 outlook. Third-quarter revenue increased 36% to $361 million, prompting the company to raise full-year revenue guidance to $1.36 billion–$1.37 billion, or approximately 38%–40% growth.
• Shield screening showed strong adoption and expanding coverage. Shield volume rose 246% to 83,000 tests, while new payer decisions are expected to bring coverage to about 100 million people by 2027; management raised its full-year Shield volume and revenue outlook.
• Oncology growth was supported by rising test volumes and product milestones. Oncology volume increased 58%, with Reveal volumes more than doubling; Guardant also received FDA approval for ESR1 monitoring, submitted Guardant360 Tissue for FDA review, and expects to launch Reveal Ultra clinically before year-end.
• Cost improvements and lower cash burn supported the path toward profitability. Non-GAAP gross margin improved to 67%, Shield cost per test fell to $330—below the company’s year-end target—and adjusted EBITDA loss narrowed to $37 million; Guardant reiterated its goal of company-wide cash-flow breakeven by the end of 2027.
• Full-year free-cash-flow-burn guidance increased. Guardant now expects $205 million–$220 million of burn, partly because $10 million–$15 million in Guardant360 Liquid CDx payments are expected to shift into 2027 due to a CMS billing-system delay; the company also plans continued investment in commercial expansion.

Guardant Health Stock Down 9.2%

Shares of Guardant Health stock traded down $15.56 during trading on Thursday, hitting $153.01. The stock had a trading volume of 4,072,426 shares, compared to its average volume of 2,200,776. Guardant Health has a 1 year low of $74.55 and a 1 year high of $191.05. The stock has a 50 day simple moving average of $170.02 and a 200 day simple moving average of $131.62. The company has a market capitalization of $20.53 billion, a PE ratio of -43.84 and a beta of 1.67.

Analysts Set New Price Targets

GH has been the topic of several research reports. Roth Capital started coverage on Guardant Health in a report on Thursday, October 22nd. They issued a “buy” rating and a $200.00 price target on the stock. Citigroup increased their price objective on Guardant Health from $150.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. TD Cowen reissued a “buy” rating on shares of Guardant Health in a research note on Tuesday, August 25th. Guggenheim lifted their target price on Guardant Health from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Finally, Morgan Stanley boosted their target price on Guardant Health from $185.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Guardant Health has an average rating of “Moderate Buy” and an average target price of $191.00.

Insiders Place Their Bets

In other Guardant Health news, CEO Amirali Talasaz sold 37,500 shares of Guardant Health stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $169.16, for a total transaction of $6,343,500.00. Following the transaction, the chief executive officer directly owned 37,500 shares in the company, valued at approximately $6,343,500. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steve E. Krognes sold 6,674 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the sale, the director directly owned 7,906 shares in the company, valued at approximately $1,389,400.44. This trade represents a 45.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 163,060 shares of company stock worth $27,538,217 in the last quarter. Corporate insiders own 5.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.